DexCom (Nasdaq: DXCM) reported earnings on Feb. 21. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), DexCom beat expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded significantly. Non-GAAP loss per share dropped. GAAP loss per share shrank.

Margins increased across the board.

Revenue details
DexCom reported revenue of $33.3 million. The 13 analysts polled by S&P Capital IQ wanted to see sales of $30.2 million on the same basis. GAAP reported sales were 49% higher than the prior-year quarter's $22.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$0.15. The 11 earnings estimates compiled by S&P Capital IQ averaged -$0.15 per share. Non-GAAP EPS were -$0.15 for Q4 versus -$0.18 per share for the prior-year quarter. GAAP EPS were -$0.12 for Q4 compared to -$0.18 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 52.6%, 490 basis points better than the prior-year quarter. Operating margin was -25.2%, much better than the prior-year quarter. Net margin was -25.5%, much better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $26.8 million. On the bottom line, the average EPS estimate is -$0.17.

Next year's average estimate for revenue is $127.3 million. The average EPS estimate is -$0.49.

Investor sentiment
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 76 members out of 173 rating the stock outperform, and 97 members rating it underperform. Among 66 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 23 give DexCom a green thumbs-up, and 43 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DexCom is outperform, with an average price target of $15.31.

Is DexCom the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.